Patients were randomly allocated to one of the following regimens: intravenous ibandronate (2 mg every 2 months or 3 mg every 3 months) plus daily oral placebo; or 2.5 mg daily oral ibandronate ...
Evidence Synthesis: Monthly oral and quarterly IV ibandronate reduce NVF risk significantly more than daily oral ibandronate and placebo, as shown by meta-analyses stratified by ibandronate dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback